Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074488 | 1.00 | CYP3A4 (0.40) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16318484 | 0.93 | CYP3A4 (0.41) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16318483 | 0.93 | CYP3A4 (0.41) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12934494 | 0.90 | CYP3A4 (0.38) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4297033 | 0.90 | STING1 (0.38) | CYP3A4STING1IRAK4 | |
| SCHEMBL4565058 | 0.89 | MMP2 (0.38) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1536529 | 0.87 | PIK3CD (0.39) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1070509 | 0.87 | PIK3CD (0.39) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL8190930 | 0.87 | PIK3CD (0.39) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19069202 | 0.85 | CYP3A4 (0.37) | CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| US-8591878-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | CYP3A4 604/4885PIK3CD 4763/4885PIK3CA 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.